Home General Biotechnology Drug Patent Expirations in December 2012

Drug Patent Expirations in December 2012

Drug Patent Expirations for December 2012

TradenameApplicantGeneric NamePatent NumberPatent Expiration
NUTROPIN DEPOTGenentechsomatropin recombinant6,051,259Dec 2, 2012
ATACAND HCTAstrazenecacandesartan cilexetil; hydrochlorothiazide5,196,444*PEDDec 4, 2012
ATACANDAstrazenecacandesartan cilexetil5,196,444*PEDDec 4, 2012
PAXIL CRGlaxosmithklineparoxetine hydrochloride5,422,123*PEDDec 6, 2012
COMBIPATCHNovartisestradiol; norethindrone acetate5,958,446Dec 12, 2012
MUSEMeda Pharmsalprostadil5,474,535Dec 12, 2012
PROHANCEBraccogadoteridol5,474,756Dec 12, 2012
PROHANCE MULTIPACKBraccogadoteridol5,474,756Dec 12, 2012
DAYTRANANoven Pharms Incmethylphenidate5,958,446Dec 12, 2012
VIVELLE-DOTNovartisestradiol5,958,446Dec 12, 2012
COMBIPATCHNovartisestradiol; norethindrone acetate5,474,783Dec 12, 2012
PROHANCEBraccogadoteridol6,143,274Dec 12, 2012
PROHANCE MULTIPACKBraccogadoteridol6,143,274Dec 12, 2012
VIVELLE-DOTNovartisestradiol5,474,783Dec 12, 2012
ALPHAGAN PAllerganbrimonidine tartrate5,424,078*PEDDec 13, 2012
SYMBICORTAstrazenecabudesonide; formoterol fumarate dihydrate5,972,919Dec 17, 2012
TASMARValeant Pharms Llctolcapone5,476,875Dec 19, 2012
ASMANEX TWISTHALERScheringmometasone furoate5,394,868*PEDDec 25, 2012
SPIRIVABoehringer Ingelheimtiotropium bromide monohydrate5,478,578Dec 26, 2012
MAXALT-MLTMerckrizatriptan benzoate5,298,520*PEDDec 29, 2012
MAXALTMerckrizatriptan benzoate5,298,520*PEDDec 29, 2012
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.